Jonah Burian
Investor at Blockchain Capital
New York, New York
Jonah Burian, Investor at Blockchain Capital is an active investor based in New York, New York. This profile covers what Jonah Burian backs, at which stage, and how founders can reach out in 2026.
Jonah Burian is an investor at Blockchain Capital.
- Investor type
- VC
- Stages
- Early Stage Venture
- Invests in
- Crypto & Web3
- Location
- New York, New York
- Typical check
- $500K
How to reach Jonah Burian
Angels and operators like Jonah Burian reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Jonah Burian
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Jonah Burian invest in?
Jonah Burian invests in Crypto & Web3, typically at Early Stage Venture. Match your sector and stage, then reach out with a personalized pitch.
What stage does Jonah Burian invest at?
Jonah Burian typically invests at Early Stage Venture. Lead with traction that fits the stage when you reach out.
What is Jonah Burian's typical check size?
Jonah Burian typically writes checks around $500K. Use it as a signal for whether your raise fits their stage.
How do I contact Jonah Burian?
Unlock Jonah Burian's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.